Ovarian cancer is the first in mortalities among gynecologic cancers in the United States, often due to late diagnosis and/or acquired platinum-resistant recurrences. This study investigates whether ...

An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study has found. Auranofin is currently undergoing trials for ...

Bleomycin in nonseminomatous germ-cell tumors: cure rate versus morbidity. The survival of 71 BRCA1-associated cancer patients (33 breast cancer, seven breast and ovarian cancer, and 31 ovarian cancer ...

Accuracy and Surgical Impact of Magnetic Resonance Imaging in Breast Cancer Staging: Systematic Review and Meta-Analysis in Detection of Multifocal and Multicentric Cancer Among the most promising ...

Research has found important new ways that the BRCA1 gene functions which could help develop our understanding of the development of ovarian and breast cancers. Research led by the University of ...

“Ovarian cancer (OC) is the third most prevalent type of gynecologic cancer affecting women after cervical and uterine cancer [1]. It is also considered the most fatal of all gynecological cancers [..

More than 14,000 women learn they have ovarian cancer each year, and despite recent advances in the treatment of the disease, the prognosis remains discouraging. For newly diagnosed patients, fewer ...

Researchers have uncovered how tumor cells interact with the immune system in ovarian cancer. Utilizing highly multiplex immunofluorescence and image analysis, they investigated how the genetic ...

A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, "Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the ...

Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46] ...

In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.